EFEKTIVITAS PENGGUNAAN OBAT ANTITUBERKULOSIS (OAT) PADA PASIEN MRD-TB DI RSUD DR. SOEKARDJO KOTA TASIKMALAYA

ZAHARA, RAISYA ATAINA (2025) EFEKTIVITAS PENGGUNAAN OBAT ANTITUBERKULOSIS (OAT) PADA PASIEN MRD-TB DI RSUD DR. SOEKARDJO KOTA TASIKMALAYA. Sarjana thesis, UNIVERSITAS BAKTI TUNAS HUSADA TASIKMALAYA.

	Text (Cover dan Abstrak) COVER DAN ABSTRAK.pdf Download (272kB)
	Text (Bab I - Bab V) BAB I - BAB V.pdf Restricted to Repository staff only Download (553kB) | Request a copy
	Text (Daftar Pustaka) DAFTAR PUSTAKA.pdf Download (226kB)

Abstract

Tuberkulosis (TB) merupakan penyakit menular yang disebabkan oleh Mycobacterium tuberculosis dan masih menjadi masalah kesehatan global. Salah satu tantangan utama adalah munculnya Multidrug-Resistant Tuberculosis (MDR-TB), yaitu tuberkulosis yang resisten terhadap minimal dua obat lini pertama: isoniazid dan rifampisin. Penelitian ini bertujuan mengevaluasi pola terapi dan keberhasilan pengobatan pasien MDR-TB di RSUD dr. Soekardjo, Tasikmalaya. Desain penelitian menggunakan metode purposive sampling berdasarkan data retrospektif pasien rawat jalan dengan diagnosis MDR-TB dari Januari 2023 hingga Januari 2025. Kriteria inklusi mencakup pasien MDR-TB dengan atau tanpa komorbid, serta memiliki data rekam medis lengkap. Pasien yang belum menyelesaikan terapi dikeluarkan dari studi. Analisis dilakukan menggunakan MedCalc untuk menghitung relative risk dan p-value. Hasil menunjukkan bahwa regimen BPaLM lebih efektif dalam meningkatkan keberhasilan terapi sebesar 87,5% (RR 0,1250; 95% CI: 0,0200–0,7819) dibanding terapi konvensional. Selain itu, terapi Bdq-Cfz-E-Mfx-Z terbukti memiliki risiko kegagalan terapi lebih rendah, masing-masing 4,3 kali (RR 4,3333; 95% CI: 1,6062–11,6910) dan 3,1 kali (RR 3,0952; 95% CI: 1,0329–9,2756) dibanding regimen konvensional lainnya. Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and remains a major global health concern. One of the main challenges in its management is the emergence of Multidrug-Resistant Tuberculosis (MDR-TB), a form of TB that is resistant to at least two first-line drugs: isoniazid and rifampicin. This study aims to evaluate the treatment patterns and therapeutic outcomes of MDR-TB patients at RSUD Dr. Soekardjo, Tasikmalaya. A purposive sampling method was applied using retrospective data from outpatients diagnosed with MDR-TB between January 2023 and January 2025. Inclusion criteria consisted of MDR-TB patients with or without comorbidities who had complete medical records. Patients who had not completed their treatment were excluded from the study. Data analysis was conducted using MedCalc software to calculate relative risk and p-values. The results showed that the BPaLM regimen was more effective in achieving treatment success, with an 87.5% improvement (RR 0.1250; 95% CI: 0.0200–0.7819) compared to conventional regimens. Furthermore, the Bdq-Cfz-E-Mfx-Z regimen demonstrated a significantly lower risk of treatment failure—by 4.3 times (RR 4.3333; 95% CI: 1.6062–11.6910) and 3.1 times (RR 3.0952; 95% CI: 1.0329–9.2756)—compared to other conventional regimens.

Actions (login required)

View Item